RxNorm 2388589

axicabtagene ciloleucel 2940000 CELLS/ML

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 2388589 unique identifier include: axicabtagene ciloleucel 2940000 CELLS/ML (12422354).

RxNorm Atom ID: 12422354 - Semantic Clinical Drug Component
axicabtagene ciloleucel 2940000 CELLS/ML

RXCUI:
2388589 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
12422354 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
axicabtagene ciloleucel 2940000 CELLS/ML - Description of concept identifier
Term Type (TTY):
SCDC - Term type in source with name and description
Term Type Name:
Semantic Clinical Drug Component - Name of term type in source
Term Type Description:
Ingredient + Strength - Description of term type in source
Code:
2388589 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_250804F - The source version
Source Date:
August 04, 2025 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom 12422354 Attributes

PropertyValueExplanation
RXN BOSS STRENGTH DENOM UNITMLRXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE1RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNITCELLSRXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE2940000RXN Boss Strength Num Value
RXN STRENGTH2940000 CELLS/MLStrength plus unit of SCDC

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Axicabtagene Ciloleucel Injection


Axicabtagene ciloleucel injection is used to treat a certain type of non-Hodgkin's lymphoma (cancer that begins in white blood cells that normally fight infection) that has returned or is unresponsive to other treatment(s) in people who have already been treated with at least two other chemotherapy medications. Axicabtagene ciloleucel injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells.
[Learn More]


* Please review the disclaimer below.